Ezetimibe, a drug approved by the Food and Drug Administration (FDA) for the treatment of hypercholesterolemia, improves NAFLD and alleviates oxidative stress by the activation of AMPK, which in turn phosphorylates p62/SQSTM1 [136]. This evidence concerns the gene SQSTM1 and Hypercholesterolemia.